Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
Portfolio Pulse from
Fennec Pharmaceuticals announced that its drug Pedmarqsi® has received a positive recommendation from NICE for preventing cisplatin-induced hearing loss in children and young people in England and Wales. This makes Pedmarqsi® the first treatment available for this condition within NHS England and Wales.
December 20, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fennec Pharmaceuticals' Pedmarqsi® has been positively recommended by NICE for preventing hearing loss in children due to cisplatin treatment, making it the first available treatment in NHS England and Wales.
The positive recommendation by NICE is a significant regulatory milestone for Fennec Pharmaceuticals, as it allows Pedmarqsi® to be the first treatment available for cisplatin-induced hearing loss in children within NHS England and Wales. This could lead to increased adoption and sales, positively impacting the company's stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90